Gen-Probe to Webcast Presentation at the Thomas Weisel Partners Healthcare Conference 2008

Thursday, August 28, 2008 General News J E 4
SAN DIEGO, Aug. 27 Gen-Probe Incorporated(Nasdaq: GPRO) announced today that the Company will present at the ThomasWeisel Partners Healthcare Conference 2008 on Wednesday, September 3, 2008 atapproximately 8 a.m. Eastern Time. The presentation is scheduled to be webcastlive and may be accessed through a link on the investors section ofGen-Probe's website at The webcast will be availablefor 30 days following the event.

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufactureand marketing of rapid, accurate and cost-effective nucleic acid tests (NATs)that are used primarily to diagnose human diseases and screen donated humanblood. Gen-Probe has approximately 25 years of NAT expertise, and received the2004 National Medal of Technology, America's highest honor for technologicalinnovation, for developing NAT assays for blood screening. Gen-Probe isheadquartered in San Diego and employs approximately 1,000 people. For moreinformation, go to

Caution Regarding Forward-Looking Statements

Any statements in this press release about our expectations, beliefs,plans, objectives, assumptions or future events or performance are nothistorical facts and are forward-looking statements. Forward-lookingstatements are not guarantees of performance. They involve known and unknownrisks, uncertainties and assumptions that may cause actual results, levels ofactivity, performance or achievements to differ materially from thoseexpressed or implied by any forward-looking statement. For information aboutrisks and uncertainties we face and a discussion of our financial statementsand footnotes, see documents we have filed with the SEC, including the Form10-Q for the year period June 30, 2008, and all subsequent periodic filingsmade with the SEC. We assume no obligation and expressly disclaim any duty toupdate any forward-looking statement to reflect events or circumstances afterthe date of this press release or to reflect the occurrence of unanticipatedevents.Contact: Paula Izidoro Investor Relations 858-410-8904

SOURCE Gen-Probe Incorporated


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
AIDS Crisis in Communities of Color Prompts Demand...
Cadence Pharmaceuticals' CEO Theodore Schroeder to...